Can-Fite BioPharma Ltd.
CANF evidence brief
What we can confirm
- Market Cap:
- $5.0M
What it means
What to watch
Prepared research question
What matters most for CANF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CANF
Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing small-molecule drugs targeting the A3 adenosine receptor (A3AR) for liver, oncological, inflammatory, and erectile dysfunction indications, with no approved products or commercial sales to date.
Key risk: No approved products
Market Cap
$5.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials for Can-Fite BioPharma Ltd..
Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing small-molecule drugs targeting the A3 adenosine receptor (A3AR) for liver, oncological, inflammatory, and erectile dysfunction indications, with no approved products or commercial sales to date.
- Can-Fite's pipeline is based on three molecules targeting the A3AR: Piclidenoson, Namodenoson, and CF602 [sec · filed 2026-03-26].
- Namodenoson has orphan drug designation for hepatocellular carcinoma (HCC) in the US and Europe and Fast Track designation from the FDA for advanced HCC [sec · filed 2026-03-26].
- As of December 31, 2025, the company reported cash and cash equivalents of $5.5 million and short-term deposits of $3.0 million [sec · filed 2026-03-26].
- The company has incurred operating losses since inception and expects to continue incurring substantial losses for the foreseeable future [sec · filed 2026-03-26].
- None of Can-Fite's product candidates have been approved for sale or marketing, and there have been no commercial sales to date [sec · filed 2026-03-26].
What works
- Namodenoson has received orphan drug designation for HCC in the US and Europe, as well as Fast Track designation from the FDA for advanced HCC, which may expedite development [sec · filed 2026-03-26].
- The company's strategy focuses on advancing product candidates closest to realizing their potential and avoiding dependency on a small number of molecules [sec · filed 2026-03-26].
- Can-Fite has a wholly owned subsidiary in France and leases office space at a low cost, indicating a lean operational structure [sec · filed 2026-03-26].
What to weigh
- The company has incurred operating losses since inception and anticipates continuing substantial losses for the foreseeable future [sec · filed 2026-03-26].
- Can-Fite has not yet commercialized any products or technologies and may never become profitable [sec · filed 2026-03-26].
- The company is dependent on only three molecules (Piclidenoson, Namodenoson, CF602) for its potential commercialization, and failure to develop them would have a material adverse effect [sec · filed 2026-03-26].
- Can-Fite will need to raise additional capital to meet business requirements, which may be costly or difficult to obtain and will dilute current shareholders' ownership [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
The company has incurred operating losses since inception and expects to continue incurring substantial losses.
“We have incurred operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.”
SEC filings · March 26, 2026
Namodenoson has orphan drug and Fast Track designations for HCC.
“Namodenoson was granted Fast Track designation by the FDA for patients with advanced HCC who failed first line treatment.”
SEC filings · March 26, 2026
No product candidates have been approved or commercialized.
“None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any of our product candidates.”
SEC filings · March 26, 2026
Cash and cash equivalents as of December 31, 2025 were $5.5 million.
“As of December 31, 2025, we had cash and cash equivalents of $5.5 million and short-term deposits of $3.0 million.”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- No approved products — None of the product candidates have been approved for sale or marketing, and there have been no commercial sales to date [sec · filed 2026-03-26].
- Cash runway limited — Cash and equivalents of $5.5M as of Dec 31, 2025, with management stating resources sufficient for only 12 months from filing [sec · filed 2026-03-26].
- Dependence on three molecules — The entire pipeline relies on three molecules (Piclidenoson, Namodenoson, CF602); failure to develop any would have a material adverse effect [sec · filed 2026-03-26].
- Need for future capital — Additional capital will be required, which may be costly or difficult to obtain and will dilute current shareholders [sec · filed 2026-03-26].
What to watch
- Progress of Namodenoson in clinical trials for HCC and MASH, given its orphan drug and Fast Track designations [sec · filed 2026-03-26].
- The company's ability to raise additional capital within the next twelve months as its cash runway is projected to be sufficient only through early 2027 [sec · filed 2026-03-26].
- Any updates on the development of Piclidenoson, the most advanced molecule, and CF602 for erectile dysfunction [sec · filed 2026-03-26].
- Regulatory milestones or partnership announcements that could affect the company's financial position or pipeline progress [sec · filed 2026-03-26].
Sources: SEC filings · Generated September 30, 2026 · How we verify sources →
Run Can-Fite BioPharma Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Can-Fite BioPharma Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$329K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 42,559 | $132K |
| citadel advisors llc | 34,150 | $106K |
| rhumbline advisers | 20,908 | $65K |
| citigroup inc | 5,482 | $17K |
| ubs group ag | 2,152 | $7K |
| osaic holdings, inc. | 450 | $1K |
| fifth third bancorp | 150 | $465 |
| wells fargo & company/mn | 125 | $388 |
| hrt financial lp | 19,383 | $60 |
| virtu financial llc | 12,908 | $40 |
Showing top 10 of 14 institutional holders of Can-Fite BioPharma Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 0.0
- Shares short
- 23,418
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CANF short interestFrequently asked questions
What is the AI investment thesis for Can-Fite BioPharma Ltd.?
Can-Fite BioPharma Ltd. is a clinical-stage biotechnology company developing small-molecule drugs targeting the A3 adenosine receptor (A3AR) for liver, oncological, inflammatory, and erectile dysfunction indications, with no approved products or commercial sales to date.
Who is the CEO of Can-Fite BioPharma Ltd.?
Mr. Motti Farbstein is the chief executive officer of Can-Fite BioPharma Ltd. (CANF).
Where is Can-Fite BioPharma Ltd. headquartered?
Can-Fite BioPharma Ltd. (CANF) is headquartered in Ramat Gan, Israel.
What therapeutic areas does Can-Fite BioPharma Ltd. focus on?
Can-Fite BioPharma Ltd. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.